Mental health and wellness company specializing on evidence-based accessible psychedelic assisted psychotherapy to treat addictions and mental conditions Numinus Wellness Inc. (TSE: NUMI) (OTCQX: NUMIF) announced having being granted approval by Health Canada to study Ayahuasca and San Pedro at its licensed, state-of-the-art research facility, Numinus Bioscience.
This development expands the license portfolio of the company as a globally recognized research center for natural psychedelic medicines and supplements. Currently, the company is carrying out studies on psilocybe species and inherent synergistic compounds.
Following renewal of Numinus Bioscience’s dealers license, the research unit has been granted permission to work with San Pedro cactus, the beta-carbolines harmaline and harmalol, and also the following botanical compounds; Banisteriopsis caapi, Psychotria viridis, Diplopterys cabrerana, Mimosa tenuiflora.
The botanical compounds play a pivotal role as they are admixtures to Ayahuasca which is a psychoactive brew made from multiple plant materials. Ayahuasca is widely consumed in Amazonian indigenous traditional practices for ceremonial, medicinal and spiritual purposes.
“There is little industry research currently being done on these botanicals. This exciting advancement at Numinus broadens our study of naturally occurring ethnobotanical substances and admixtures and the synergies of the compounds. This is a first step in helping us better understand their mechanisms and potential therapeutic applications,” said the chief science officer of Numinus, Sharan Sidhu.